Search Results for: drug patents

In a press release, Johnson and Johnson “announced their intention not to enforce the patents they own and control on the antiretroviral (ARV) drug darunavir provided the darunavir product is medically acceptable and is used only in resource-limited settings,” which J&J defines as the 48 UN defined Least Developed Countries plus any other country in sub-Saharan Africa. This is the KEI statement on the J&J darunavir announcement.

Continue Reading →

On Tuesday, 27 November 2012, KEI filed an amicus brief to the Supreme Court of the United States in the case Ninestar Technology Co., et. al. v. International Trade Commission, et. al., supporting the Petitioners’ petition for writ of certiorari (essentially asking the Supreme Court to agree to hear the case). This case involves the application of the patent exhaustion doctrine (also known as the first sale doctrine), specifically whether the United States applies a system of international exhaustion of rights or national exhaustion of rights. Continue Reading →

On 7 November 2012, India delivered the following intervention under agenda item M, “Intellectual Property and Innovation”.

We thank the delegations of Brazil and the United States for tabling an agenda item on “Intellectual Property and Innovation” which we understand is a standalone item.

Continue Reading →

On 6 November 2012, the United States delivered the following intervention under agenda item F, “Review under Paragraph 8 of the Decision on the Implementation of Paragraph 8 of the Doha Declaration on the TRIPS Agreement and Public Health”.

F. REVIEW UNDER PARAGRAPH 8 OF THE DECISION ON THE IMPLEMENTATION OF PARAGRAPH 6 OF THE DOHA DECLARATION ON THE TRIPS AGREEMENT AND PUBLIC HEALTH

• Thank you, Mr. Chairman, and the Secretariat, for the report on the status of notifications of acceptance of the 2005 Protocol Amending the TRIPS Agreement.

Continue Reading →

The US Food and Drug Administration (FDA) publishes the “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations” in both an annual paper bound edition and web-based searchable database (available here). As part of a larger effort to expand access to government data, the FDA provides monthly updates of the underlying data here.

Continue Reading →